{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.138","meta":{"versionId":"6","lastUpdated":"2021-03-06T01:00:16.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138","version":"20210306","name":"Granisetron Transdermal","status":"active","date":"2021-03-06T01:00:16-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"825003","display":"168 HR granisetron 0.129 MG/HR Transdermal System"}]}]},"expansion":{"identifier":"urn:uuid:ea4f20ae-dacc-4ce7-b6ab-f077815fde21","timestamp":"2022-06-10T08:00:46-04:00","total":1,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"825003","display":"168 HR granisetron 0.129 MG/HR Transdermal System"}]}}